Liver News and Research

RSS

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Salix Pharmaceuticals, Inc. today announced that the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010) will be an important venue for ongoing discussion of hepatic encephalopathy, or HE.

1 Nov 2010

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Tibotec Pharmaceuticals announced today the company will present the results of a Week-24 planned interim analysis of the phase 2 response-guided PILLAR study in treatment-naive patients with chronic genotype 1 hepatitis C virus (HCV) at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA., USA. The data will be presented as part of a late-breaker oral presentation on Monday, November 1.

1 Nov 2010

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.

1 Nov 2010

Researchers generate bioengineered human liver organoid using bioscaffold

Researchers at Wake Forest University Baptist Medical Center's Institute for Regenerative Medicine demonstrated the generation of a bioengineered human liver organoid using a liver bioscaffold made from an intact liver extracellular matrix, and filled (seeded) with primary human liver progenitor and endothelial cells.

1 Nov 2010

Gilead presents Phase IIa data for HCV therapy at The Liver Meeting 2010

Gilead Sciences, Inc. today announced data from a Phase IIa study showing that its investigational compounds GS 9190 and GS 9256, used in conjunction with current standard of care therapies, produced substantial suppression of the hepatitis C virus (HCV) within 28 days of treatment.

1 Nov 2010

Anadys presents data of ANA598 for hepatitis C treatment at AASLD Annual Meeting

Anadys Pharmaceuticals, Inc. today announced the ANA598 data to be presented at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston, MA.

1 Nov 2010

‘Off the shelf’ new livers from stem cells, glimmer of hope

A researcher team has successfully produced a small-scale version of a human liver in the laboratory using stem cells. This could be a boon for patients waiting for liver transplants although it will take years to perfect the procedure say researchers.

31 Oct 2010

Study finds SBRT therapy delays pancreatic cancer progression

For pancreatic cancer patients unable to undergo surgery the only known cure for this form of cancer a highly targeted cancer radiation therapy may help slow cancer progression and lessen disease symptoms, according to researchers at Henry Ford Hospital in Detroit.

30 Oct 2010

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it will present several poster presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases being held in Boston, Mass from October 29 - November 2, 2010.

30 Oct 2010

Study suggests curcumin may be an effective therapy for liver fibrosis

Curcumin, a chemical that gives curry its zing, holds promise in preventing or treating liver damage from an advanced form of a condition known as fatty liver disease, new Saint Louis University research suggests.

30 Oct 2010

Merck reports $342 million net income for 2010 third quarter

Merck & Co., Inc. today announced financial results for the third quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the third quarter of $0.85, which excludes purchase accounting adjustments, restructuring costs, merger-related expenses and a $950 million legal reserve.

29 Oct 2010

Mechanism that controls embryonic development could also prevent cancer

Researchers from Mount Sinai School of Medicine have identified a mechanism controlling the function of a protein that binds to DNA during embryonic development and may function to prevent abnormal tumor growth.

29 Oct 2010

Study finds impact of pre-transplant BMI on post liver transplant survival in pediatric population

A new study from the University of Washington reported obese children are at increased mortality risk in later years following primary liver transplantation (LT).

29 Oct 2010

New approach for early diagnosis of pancreatic cancer

Pancreatic tumors are one of the most lethal cancers, with fewer than five percent of patients surviving five years after diagnosis. But a new study that peers deeply into the genetics of pancreatic cancer presents a bit of good news an opportunity for early diagnosis. In contrast to earlier predictions, many pancreatic tumors are, in fact, slow growing, taking nearly 20 years to become lethal after the first genetic perturbations appear.

29 Oct 2010

Olive oil protects against oxidative damage of hepatic tissue

Extra-virgin olive oil can protect the liver from oxidative stress. Researchers writing in BioMed Central's open access journal Nutrition and Metabolism exposed rats to a moderately toxic herbicide known to deplete antioxidants and cause oxidative stress, finding that those rats fed on a diet containing the olive oil were partially protected from the resulting liver damage.

29 Oct 2010

New iPSC cell lines could help in treating patients with lung diseases

A team of researchers from Boston University's Center for Regenerative Medicine and the Pulmonary Center have generated 100 new lines of human induced pluripotent stem cells (iPSC) from individuals with lung diseases, including cystic fibrosis and emphysema. The new stem cell lines could possibly lead to new treatments for these debilitating diseases.

29 Oct 2010

Malvern Zetasizer Nano used to characterize environmentally responsive nanoparticles

The rapid, real-time measurement capabilities of the Zetasizer Nano system from Malvern Panalytical have enabled quantified nanoscale characterization of the environmental sensitivity of novel solubilization nanoparticles.

From Malvern Panalytical 28 Oct 2010

Pharmasset's PSI-938 phase I monotherapy trial shows positive result for HCV treatment

Pharmasset, Inc. reported positive preliminary results today from its phase I monotherapy trial of PSI-352938 for the treatment of chronic hepatitis C (HCV). PSI-938 is a guanosine nucleotide analog polymerase inhibitor in development for the treatment of chronic HCV infection.

28 Oct 2010

Pancreatic cancer develops and spreads more slowly than thought before

Pancreatic cancer develops and spreads much more slowly than scientists have thought, according to new research from Johns Hopkins investigators. The finding indicates that there is a potentially broad window for diagnosis and prevention of the disease.

28 Oct 2010

Mirada Medical and Moffitt Cancer Center enter joint development agreement

Mirada Medical Limited, the fast growing international company focused on advanced oncology imaging, announced today that they have signed an agreement with Moffitt Cancer Center, Tampa, FL, one of the USA's top centers for cancer treatment and oncology research.

28 Oct 2010

Liver News and Research

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Researchers generate bioengineered human liver organoid using bioscaffold

Gilead presents Phase IIa data for HCV therapy at The Liver Meeting 2010

Anadys presents data of ANA598 for hepatitis C treatment at AASLD Annual Meeting

‘Off the shelf’ new livers from stem cells, glimmer of hope

Study finds SBRT therapy delays pancreatic cancer progression

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Study suggests curcumin may be an effective therapy for liver fibrosis

Merck reports $342 million net income for 2010 third quarter

Mechanism that controls embryonic development could also prevent cancer

Study finds impact of pre-transplant BMI on post liver transplant survival in pediatric population

New approach for early diagnosis of pancreatic cancer

Olive oil protects against oxidative damage of hepatic tissue

New iPSC cell lines could help in treating patients with lung diseases

Malvern Zetasizer Nano used to characterize environmentally responsive nanoparticles

Pharmasset's PSI-938 phase I monotherapy trial shows positive result for HCV treatment

Pancreatic cancer develops and spreads more slowly than thought before

Mirada Medical and Moffitt Cancer Center enter joint development agreement

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News